Introduction: Cancer was the second leading cause of death in hospitals after cardiovascular disease in Burkina Faso in 2020. Radiotherapy is involved in the treatment of 60 % of cancers. The radiotherapy center inaugurated in April 2021 allowed to irradiate cancer in Ouagadougou for the first time. Thus, it was possible to perform concurrent chemoradiotherapy (CCRT). The aim of our study was to describe the epidemiological, diagnostic and therapeutic profiles of cancer patients treated with CCRT in Ouagadougou
Materials and methods: Descriptive cross-sectional study with retrospective collection from May 1, 2021 to April 30, 2022 from the medical records of patients who have benefited from a CCRT. Included in the study was any patient with a confirmed cancer diagnosis whose medical record was presented in a multidisciplinary meeting (MDM) with validation of a neoadjuvant or exclusive CCRT. Chemotherapy was performed in the clinical hematology oncology department and radiotherapy in the radiotherapy center of University Teaching Hospital Bogodogo.
Results: We included 41 patients. The mean age was 54.85 years [35 to 80 years]. Women accounted for 90.2% of cases. Cervical cancers accounted for 87.8% of cases, followed by ENT cancers with 7.3%. Squamous cell carcinoma was the most common histological type. External radiotherapy was used with total doses ranging from 50 to 70 Gy. Chemotherapies were cisplatin (40 mg/m2) or carboplatin (AUC2).
Conclusion: CCRT has improved the treatment of cancer patients who previously only received chemotherapy and/or surgery when medical evacuation out of the country was not possible

Concurrent chemoradiotherapy Cancers Ouagadougou